Aging is the main risk factor for Alzheimer's disease. Among other characteristics, it shows changes in inflammatory signaling that could affect the regulation of glial cell activation. We have shown that astrocytes prevent microglial cell cytotoxicity by mechanisms mediated by TGFb1. However, whereas TGFb1 is increased, glial cell activation persists in aging. To understand this apparent contradiction, we studied TGFb1-Smad3 signaling during aging and their effect on microglial cell function. TGFb1 induction and activation of Smad3 signaling in the hippocampus by inflammatory stimulation was greatly reduced in adult mice. We evaluated the effect of TGFb1-Smad3 pathway on the regulation of nitric oxide (NO) and reactive oxygen species (ROS) secretion, and phagocytosis of microglia from mice at different ages with and without in vivo treatment with lipopolysaccharide (LPS) to induce an inflammatory status. NO secretion was only induced on microglia from young mice exposed to LPS, and was potentiated by inflammatory preconditioning, whereas in adult mice the induction of ROS was predominant. TGFb1 modulated induction of NO and ROS production in young and adult microglia, respectively. Modulation was partially dependent on Smad3 pathway and was impaired by inflammatory preconditioning. Phagocytosis was induced by inflammation and TGFb1 only in microglia cultures from young mice. Induction by TGFb1 was also prevented by Smad3 inhibition. Our findings suggest that activation of the TGFb1-Smad3 pathway is impaired in aging. Age-related impairment of TGFb1-Smad3 can reduce protective activation while facilitating cytotoxic activation of microglia, potentiating microglia-mediated neurodegeneration.
Introduction
Alzheimer's disease (AD) is characterized by the deposition of bamyloid (Ab) plaques and neurofibrillary tangles in brain parenchyma (Hardy and Selkoe, 2002) , both of which are intimately associated with activated microglia and astrocytes. Glial cells have an important role in innate immunity, being the main producers of inflammatory mediators. Depending on the activation status, they secrete anti-inflammatory cytokines such as interleukin 10 (IL10) and transforming growth factor b (TGFb1), pro-inflammatory cytokines such as interleukin 1b (IL1b), tumor necrosis factor a (TNFa) and interferon gamma (IFNc), as well as reactive species such as nitric oxide (NO) and reactive oxygen species (ROS) including superoxide radicals (O 2 À ) (von Bernhardi et al., 2010; von Bernhardi and Eugenín, 2012) . In addition, there is solid evidence that glial cells participate in Ab clearance (Alarcón et al., 2005; Paresce et al., 1996) . When microglial cells are stimulated, production of inflammatory cytokines increases, whereas anti-inflammatory cytokines decrease (Ramírez et al., 2008) .
TGFb1 is a potent regulator of cytotoxicity and neuroinflammation in the nervous system. We have reported regulation of microglial cell cytotoxic activation by soluble factors, including TGFb1 There is evidence that TGFb1 can be both beneficial and deleterious for AD. It has been implicated on the increased deposition of Ab in blood vessels and meninges (Wyss-Coray et al., 1997) , and the increased production of Ab by astrocytes (Lesne et al., 2003) in APP/TGFb1 transgenic mice. In contrast, other studies have shown that TGFb1 has anti-amyloidogenic roles, reducing Ab
